Ocumension Initiates Second Phase III Denali Study for OT-301 in US
China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...
2022
Nankai University Establishes Postgraduate Practice Base with China Resources Biopharma
The College of Pharmacy at Nankai University has established a postgraduate practice base at the...
Yiming and WZ Biosciences Collaborate on mRNA Process Platform
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, and compatriot firm WZ...
BeiGene’s Brukinsa Receives Multiple Marketing Approvals in Latin America
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced receiving multiple marketing approvals...
Zhaoke Ophthalmology Completes Enrollment for Intrarosa Phase III Trial
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has completed...
JW Therapeutics Partners with 2seventy bio to Develop Cell Therapy Platform
China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio...
Ascletis Pharma Files IND for Monkeypox Antiviral ASC10 with FDA
China-based Ascletis Pharma Inc. (HKG: 1672) announced the submission of an Investigational New Drug (IND)...
Simcere Receives FDA Clearance for Clinical Study of SIM0237
China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the US...
Ping An Life Insurance Reports Q3 Results, Advances Healthcare Strategy
Ping An Life Insurance Company of China Ltd released its 2022 Q3 financial report, showing...
United Labs Gains NMPA Approval for Ozempic Biosimilar IND
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...
China’s NMPA Issues New Drug Recall Management Measures
The National Medical Products Administration (NMPA) has released the “Drug Recall Management Measures,” which took...
AccuMedical’s Blood Flow-Guided Stent Wins NMPA Approval for Brain Aneurysms
AccuMedical Beijing Ltd has secured approval from China’s National Medical Products Administration (NMPA) for its...
InxMed and Huaota Bio Partner to Develop Novel Solid Tumor Combination Therapy
China-based InxMed (Nanjing) Co., Ltd has entered into a strategic partnership with Shanghai Huaota Biopharmaceutical...
LEPU ScienTech Medical Technology Sets IPO Price Range Ahead of Hong Kong Listing
China-based LEPU ScienTech Medical Technology (Shanghai) Co., Ltd is gearing up for an initial public...
WuXi AppTec Posts Stellar Q3 2022 Results with 209% Profit Surge
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its Q3 2022 financial...
OriginCell’s CAR-T Therapy Receives FDA Orphan Drug Designation for Multiple Myeloma
Shanghai-based tumor immunotherapy specialist OriginCell Therapeutics has announced that its investigational autologous chimeric antigen receptor...
Novartis Q3 Revenues Rise 4% YOY; China Sales Expand Despite COVID Lockdowns
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported a 4% year-on-year (YOY) increase in global...
ImmVira Secures Series C+ Financing to Advance Oncolytic Virus and Exosome Programs
China-based biotech ImmVira has successfully secured its Series C+ financing, entering into agreements with a...
Ascentage Pharma Files for Phase Ib/II Study of Bcl-2 Inhibitor in Systemic Lupus Erythematosus
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the submission of a clinical filing with the...
Shanghai Henlius’ PD-1 Inhibitor Serplulimab Gains Australian Clearance for Phase III Study
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving regulatory clearance in Australia to...